Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must be 18 years of age or older at time of enrollment~* may be male or female~* Have had a diagnosis of plaque-type psoriasis at least 6 months prior to screening~* Have plaque-type psoriasis covering at least 10% of total BSA at baseline~* Have previously received PUVA and/or other systemic treatment for psoriasis~Exclusion Criteria:~* Have non-plaque forms of psoriasis~* Have a history of drug-induced psoriasis~* Are pregnant, nursing, or planning pregnancy within 12 months of enrollment~* Have had any previous treatment with infliximab or any therapeutic agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).